The estimated Net Worth of Michael Morrissey is at least $27.5 Millón dollars as of 28 August 2023. Dr Morrissey owns over 360,000 units of Exelixis Inc stock worth over $25,178,558 and over the last 22 years he sold EXEL stock worth over $0. In addition, he makes $2,349,812 as CEO y Pres & Director at Exelixis Inc.
Dr has made over 67 trades of the Exelixis Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 360,000 units of EXEL stock worth $5,511,600 on 28 August 2023.
The largest trade he's ever made was exercising 460,000 units of Exelixis Inc stock on 20 April 2020 worth over $2,534,600. On average, Dr trades about 41,618 units every 36 days since 2003. As of 28 August 2023 he still owns at least 945,496 units of Exelixis Inc stock.
You can see the complete history of Dr Morrissey stock trades at the bottom of the page.
Dr. Michael M. Morrissey is the CEO, Pres & Director at Exelixis Inc.
As the CEO y Pres & Director of Exelixis Inc, the total compensation of Dr Morrissey at Exelixis Inc is $2,349,812. There are no executives at Exelixis Inc getting paid more.
Dr Morrissey is 60, he's been the CEO y Pres & Director of Exelixis Inc since . There are 10 older and 10 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey y Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Exelixis Inc executives and other stock owners filed with the SEC include: